Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT bezuclastinib study in nonadvanced systemic mastocytosis
NL-OMON60951Phase 2Active, not recruiting
- Sponsor
- Cogent Biosciences
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bezuclastinib in systemic mastocytosis (SM), indolent systemic mastocytosis (ISM) and bone marrow mastocytosis (BMM) (4 arms), sponsored by Cogent Biosciences. Primary endpoints: Dose selection and safety, Week 24 symptom score change and 1 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)indolent systemic mastocytosis (ISM)bone marrow mastocytosis (BMM)
Beyond the preview
Go deeper on NL-OMON60951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60951.